Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
Despite these advances, Black women are still twice as likely as white women to die of breast cancer.
Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.
Tecentriq after surgery and chemotherapy delayed recurrence in people with Stage II or III non-small-cell lung cancer.
Prolonged delays in cancer screening for low-income women during the pandemic threaten to increase existing health disparities.
Some people with blood cancers, however, may not be as well protected.
National LGBT Cancer Network releases largest-ever survey of LGBTQIA+ cancer survivors.
A companion study will look at liver biopsy results to confirm these findings from noninvasive tests.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.
Alzheimer’s advocates laud the approval of Aduhelm, but experts raise questions about its effectiveness and cost.
Cancer screenings have dropped precipitously due to the COVID-19 pandemic.
It’s well known that some viruses can cause cancer—but others are cancer killers.
The Food and Drug Administration created its accelerated approval program to enable more rapid approval of therapies for serious conditions.
Here are the latest new cancer drugs approved by the Food and Drug Administration.
Several new medications for kidney cancer have been approved in recent years.
PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.